Start a new topic and get direct answers from the Expert Advice Community.
CREATE NEW TOPIC +Guest
ISO 27001 does not require a "minimum" number of risks, only that relevant risks are identified and treated.
Considering that, the auditor will be more concerned about the quality of the identified risks (i.e., how relevant they are for the organizations) than their quantity. The single point you need to pay attention to is to not overlook obvious risks, i.e., risks that someone with proper competence to the process or asset would easily identify. To mitigate this risk you need to include in the risk assessment the personnel involved with the process or asset.
As for the number of risks (please note that the word "scenarios" is more adequate when talking about business continuity), you mentioned, 200 is a good number. To have a parameter, when using the asset-threat-vulnerability approach, a small organization generally identifies between 50 to 100 assets, with 3 vulnerabilities and 2 threats for each asset, so they identify between 300 to 600 risks.
An important thing to note is that risk for which you already have implemented controls (and you will only accept the risk) also count for your relevant risks.
These articles will provide you a further explanation about risk assessment and treatment:
it's regarding Module 8: Data transfers and managing third parties in the DPO courseThe lecturer explains that there are certain countries that need binding corporate rules between companies transferring to each other who are operating under the same parent company. He explains that there are countries identified as having an adequate level of data protection (i.e the EU member states), and then explains that certain countries were not yet recognized have adequate protection such as the United States was not recognized as having the adequate level of data protection. Is this list of countries still up to date?
You can find the current list on the website of the European Commission here: https://ec.europa.eu/info/law/law-topic/data-protection/international-dimension-data-protection/adequacy-decisions_enJapan and the United States (limited to the Privacy Shield framework) were added.
Are entities in these countries still required to form binding corporate rules?
The course explained that binding corporate rules are suitable for large-size companies belonging to the same group, while other companies better use data transfer agreements.
However, entities located in the United States can now transfer data based on an adequacy decision instead of Binding corporate rules. In fact, Article 46 GDPR states that transfer on the basis of binding corporate rules happens in the absence of a decision under Article 45 GDPR.
You can find more information here:
You may also consider enrolling in this online EU GDPR Foundations Course: EU GDPR Foundations Course
You can start by identifying your relevant interested parties. For example:
Then, considering the purpose of your organization, put yourself in the shoes of your relevant interested parties and list what they expect from your organization. One can think about: safe food and correctly labeled and packaged food. What happens if food is not safe or not correctly labeled and packaged?
As key performance indicators, your organization can have effectiveness indicators:
As key performance indicators, your organization can also have indicators about government and general public perception/opinion about the results of the public health unit work.
Then, your organization can have indicators about the amount of work done real versus planned. For example:
As a rule of thumb consider indicators concerning:
You can find more information about indicators below
The QMS scope sets the borders where the QMS is implemented according to the criteria. An example of a QMS could be:
Other examples could be:
The QMS Criteria sets the rules to be followed. Normally they are divided in three groups:
QMS Objectives can be (for example):
You can find more information about these topics in the following links:
Yes, you need to prove that your prosthetic liner is biocompatible with the human body. To prove it, you need to perform certain tests according to the ISO 10993-1:2018 Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process. Guidance on which tests you need to perform you can find in Annex A of this standard. The number and scope of tests will depend on the length of contact of the medical device with the skin, the type of contact, and the like.
Considering the test for durability, you need to prove how long your product is stable when using in compliance with instructions of use. This includes, for example: how long the prosthesis is worn during the day, whether it is properly maintained, whether it is left somewhere in the strong sun or not.
As for testing, I don’t know what part of the world you’re in. If you are in Europe, there is a whole chain of Eurofins labs that do different tests, so you can ask them.
Hi, my question concerns companies that provide sales, service, repair, and installation services to customers. Obviously, they don't have control over the outsourced process, as it can only be justified by legal manufacturer, not distributors. Do you have any advice for managing the outsourced process in such cases? Also, I would appreciate it if you could point out any specific regulation under UKMDR that would be applicable to this matter.
Inclusions and exclusions in the scope of ISMS will depend on the information, your organization wants to protect.
You need to identify in which part of your company is your most valuable information - see the details here: How to define the ISMS scope https://advisera.com/27001academy/knowledgebase/how-to-define-the-isms-scope/
For example, if the most important information is about new products, then the Research & Development process/department must be in the scope. If the most important information is about customers, then the Customer support process/department must be in the scope. You can also define all the organization's information as part of the ISMS scope.
This article can provide you further answer about integrating management systems (the general concept applies to your case):
These materials will also help you regarding scope definition:
Thank you for sharing about 4 effective risk mitigation strategies, these will be really helpful for me. I love reading this blog; it talks so much about planning a great idea about it. Keep sharing such informative articles in future, will be appreciated. See @ https://parapet.com/Solution****************************
ISO 9001:2015 does not prescribe a specific method. Clause 7.4 mentions the use of:
So, about communicating to senior management we need to decide first what do they want or need to receive. Perhaps:
Then, decide frequency, the when: Weekly? Monthly? Quarterly?
And the how – Meeting report? Special report? Digital dashboard?
The following material will provide you information about communication:
Conformity assessment is a process that is used to demonstrate that a product meets specified requirements. In the case of medical devices, it means that conformity assessment is a process of demonstrating whether the requirements of MDD (93/42/EEC) or MDR (2017/745) relating to the device have been fulfilled. So, all documentation, tests, and reports according to the applicable regulations need to be done. It means that you need to define your processes in the way to collect all of it.
Here you have a direct link to Annex 9 of the MDR